The aim of this study is to investigate and to compare the bioavailability of MP29-02 and
fluticasone propionate in nasal tissue after nasal application. This may provide a rational
basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has
demonstrated the efficacy of the twice-daily treatment; however, so far, no data are
available on the local tissue concentrations of MP29-02 after topical application.